• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • Q&A
    • Videos
    • Comment
    • Analysis
    • People moves
    • In Profile
  •  
    Analysis
    • Videos
    • Q&A
    • Comment
    • In Profile
    • Podcast
    • Fundraising
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Nordics

EQT exits Gambro to Baxter

  • Karin Wasteson
  • 04 December 2012
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

EQT and Investor AB have sold the remaining division of Swedish healthcare business Gambro Group to trade player Baxter International for SEK 26.5bn.

The transaction is expected to be completed during the first half of 2013. EQT held 51% of Gambro Group via its EQT IV fund prior to the sale, while Investor AB owned the remaining 49%.

In 2006, EQT and Investor AB delisted Gambro Group from the Stockholm Stock Exchange through a joint public offer for a total value of SEK 35bn. The debt financing was arranged by Citigroup and Morgan Stanley. The business was streamlined after the delisting and the group split into three independent parts – Gambro Healthcare (dialysis clinics), Caridian BCT (blood technology) and Gambro Renal Products (dialysis equipment).

In 2007 Gambro Healthcare was acquired by private equity fund Bridgepoint for SEK 6.1bn, the first step in the streamlining process. The company was sold in an auction process run by Goldman Sachs. Other bidders for Gambro Healthcare included 3i and Warburg Pincus. The sale of the healthcare division was part of a value-creation plan implemented by Investor AB and EQT when they de-listed the company.

Japanese medical technology company Terumo Corporation bought Caridian BCT in 2011 for $2.6bn.

EQT's exit of Gambro to Baxter means that all parts of formerly listed Gambro Group now have new owners. The total transaction value from the three divestments amounts to approximately SEK 50bn.

Company
Gambro is headquartered in Stockholm and was founded in 1964 in Lund, where most of the company's Swedish operations are still based. In total, it employs 11,000 people in more than 40 countries.

Gambro was divided into three businesses: Gambro Renal Products, Gambro Healthcare and Caridian BCT. Gambro Renal Products offers products, therapies and services for both in-centre and home dialysis, as well as for blood purification in intensive care units.

Gambro Healthcare provides renal care services and offers a full range of end-stage renal disease treatment and patient care, while Gambro BCT focuses on apheresis and cell therapy.

People
Guido Oelkers is president and CEO of Gambro Renal Products. Harry Klagsbrun is a partner at EQT in Sweden.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Nordics
  • Healthcare
  • Now researching
  • Exits
  • Sweden
  • EQT
  • Trade sale

More on Nordics

VC Spotlight: Climentum Capital fund to announce 10th investment this month; aims for final close at EUR 75m end-Sept
VC Spotlight: Climentum Capital fund to announce 10th investment this month; aims for final close at EUR 75m end-Sept

The GP expects to launch its second fund in 2025 with a target size of EUR 100m-EUR 125m

  • Nordics
  • 16 August 2023
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs

Stockholm-based investor is considering divestments, although challenging market remains a barrier

  • Nordics
  • 26 May 2023
3i to invest in Danish children's brand Konges Sløjd
3i to invest in Danish children's brand Konges Sløjd

Deal aims to support the baby and children apparel group expand in Asia and the US

  • Nordics
  • 21 June 2022
HG-backed Visma to divest IT consulting unit to CVC
HG-backed Visma to divest IT consulting unit to CVC

Sponsor will invest in the carve-out from the Norwegian business software and IT provider via Fund VIII

  • Nordics
  • 16 June 2022

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013